Gemfibrozil

Introduction Overview

Generic Name

gemfibrozil

Brand Name

Lopid

Dosage Form

oral tablet (600 mg)

Drug Class

Fibric acid derivatives

Pharmacokinetics

Absorption:
Gemfibrozil is rapidly and well absorbed following oral administration, with peak plasma concentrations typically achieved within 1 to 2 hours after dosing. Its bioavailability is sufficient to exert pharmacologic effects, although food may slightly delay absorption without significantly affecting overall bioavailability. The drug's lipid-soluble nature facilitates gastrointestinal absorption. Clinical studies have demonstrated that administering gemfibrozil approximately 30 minutes before meals maximizes its therapeutic effect, which aligns with recommended dosing schedules.

Distribution:
Following absorption, gemfibrozil demonstrates extensive plasma protein binding, primarily to albumin, with binding rates exceeding 95%. This high plasma protein binding limits free drug concentration but allows for significant distribution into various tissues. The volume of distribution is moderate, indicating distribution beyond the vascular compartment but not extensive tissue sequestration. Gemfibrozil does not readily cross the blood-brain barrier, minimizing CNS-related adverse effects. Distribution parameters are clinically relevant when considering potential drug interactions with other highly protein-bound drugs.

Metabolism:
Gemfibrozil undergoes extensive hepatic metabolism predominantly through glucuronidation pathways, specifically conjugation via UDP-glucuronosyltransferase enzymes. Oxidative metabolism via cytochrome P450 enzymes plays a minor role. The formation of gemfibrozil glucuronide is the major metabolic pathway and contributes to both pharmacologic activity and elimination. Metabolic pathways may be subject to variation based on genetic polymorphisms or concomitant medications, influencing drug levels and response.

Elimination:
The elimination half-life of gemfibrozil is approximately 1.5 hours, with clinical dosing twice daily maintaining effective plasma concentrations. The drug and its metabolites are primarily excreted renally, with about 70% eliminated via urine, mainly as glucuronide metabolites. A lesser extent is excreted in feces. Renal function plays a significant role in clearance; therefore, severe renal impairment may necessitate dosing adjustments or monitoring. Hepatic elimination is also notable given the extensive metabolism. Understanding gemfibrozil’s elimination pathways is essential for assessing risks in patients with hepatic or renal dysfunction.

Dosage Forms

Available Dosage Forms:
Gemfibrozil is commercially available as oral tablets, specifically in a 600 mg dosage strength. The tablets are formulated for oral administration and designed to be taken as per prescribed schedules.

Dosages for Adults and Adolescents:
The standard adult dosing regimen for gemfibrozil in the treatment of hyperlipidemia (including hypertriglyceridemia, and hyperlipoproteinemias Types IIb, IV, and V) is 600 mg administered orally twice daily. The doses are typically given 30 minutes before the morning and evening meals to optimize absorption and efficacy. This dosing schedule is consistent across various lipid disorders, including the reduction of coronary heart disease risk in selected patients.

Specific Patient Populations:
Dosing adjustments are generally not well-defined for special populations such as pediatric or elderly patients, but caution is warranted. Patients with severe hepatic or renal impairment are contraindicated or require careful assessment due to altered metabolism and elimination. Clinical monitoring and potential dose modifications are essential in these groups to reduce toxicity risks. There is limited information regarding use in pregnancy and breastfeeding, and risks versus benefits should be carefully evaluated. Overall, gemfibrozil dosing must be individualized based on clinical response and safety monitoring.

Mechanism Of Action

Gemfibrozil is a member of the fibric acid derivatives class and primarily functions by activating peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor involved in the regulation of lipid metabolism genes. Upon activation, PPARα modulates the transcription of genes that enhance the oxidation of fatty acids, leading to a reduction in triglyceride-rich lipoproteins such as very low-density lipoprotein (VLDL).

At the molecular level, gemfibrozil upregulates the expression of lipoprotein lipase, an enzyme critical in hydrolyzing triglycerides in circulating chylomicrons and VLDL particles. Concurrently, it decreases hepatic production of apolipoprotein C-III, an inhibitor of lipoprotein lipase, further enhancing triglyceride clearance. This dual action results in significant lowering of serum triglyceride levels.

Gemfibrozil also modestly increases high-density lipoprotein (HDL) cholesterol by enhancing apolipoprotein A-I and A-II synthesis, contributing to reverse cholesterol transport. Its effects on low-density lipoprotein (LDL) cholesterol are variable, sometimes modestly lowering levels particularly in certain hyperlipoproteinemia phenotypes.

Clinically, these mechanistic actions translate into decreased plasma triglycerides and altered lipoprotein profiles, reducing the risk of pancreatitis and cardiovascular events in appropriate patient populations. Compared to statins, which primarily inhibit cholesterol biosynthesis, gemfibrozil’s mechanism is focused on triglyceride metabolism, making it useful in hypertriglyceridemic states. Research corroborates its efficacy in combination therapy and as monotherapy in specific dyslipidemias, with careful monitoring due to potential adverse effects.

Pharmacological Actions

Activation of peroxisome proliferator-activated receptor alpha (PPARα) leading to altered gene expression involved in lipid metabolism.
Increase in lipoprotein lipase activity promoting hydrolysis and clearance of triglyceride-rich lipoproteins.
Reduction in hepatic synthesis of apolipoprotein C-III, enhancing lipoprotein lipase function and lipid clearance.
Modest elevation of high-density lipoprotein (HDL) cholesterol levels via increased apolipoprotein A-I and A-II synthesis.
Reduction of serum triglycerides and very low-density lipoprotein (VLDL) concentrations.
Variable effect on low-density lipoprotein (LDL) cholesterol, often modestly lowering it in hyperlipoproteinemia Type IIb.
Improvement in lipid profile reducing the risk of pancreatitis associated with severe hypertriglyceridemia.
Potentiation of reverse cholesterol transport through increased HDL levels.
Reduction in the incidence of cardiovascular events in certain patient subsets with combined dyslipidemia.
Influence on hepatic fatty acid oxidation enhancing catabolism of circulating fatty acids.
No significant central nervous system penetration, limiting CNS-related side effects.
High plasma protein binding affecting drug distribution and potential drug-drug interactions.
Metabolism via glucuronidation pathways leading to active metabolites contributing to pharmacologic effects.

Therapeutic Or Clinical Uses

Treatment of severe hypertriglyceridemia, particularly in patients at risk of pancreatitis associated with Types IV and V hyperlipoproteinemia.
Adjunctive therapy to dietary management for reduction of elevated cholesterol and triglyceride levels.
Management of hyperlipoproteinemia Type IIb (mixed hyperlipidemia with elevated LDL and VLDL) to reduce cardiovascular risk.
Reduction of coronary heart disease risk in patients without a history or symptoms of existing CHD who have not adequately responded to other treatments.
Improvement of lipid profiles in patients with dyslipidemias characterized by low HDL cholesterol.
Lowering of serum triglycerides in patients with persistently elevated levels despite dietary and lifestyle modification.
Adjunct therapy to prevent cardiovascular events including stroke and myocardial infarction in select patients.
Treatment of hyperlipoproteinemia Type IV to decrease elevated VLDL concentrations.
Management of hyperlipoproteinemia Type V involving elevated chylomicrons and VLDL fractions.
Use in patients who have insufficient response to other lipid-lowering agents such as statins or bile acid sequestrants.
Prevention of pancreatitis episodes in patients with severe hypertriglyceridemia attributable to genetic or secondary causes.
Treatment option in patients intolerant to or contraindicated for certain statins or other lipid-lowering medications.
Improvement of lipid abnormalities as part of comprehensive therapeutic programs including diet and exercise.

Side Or Adverse Effects

Gastrointestinal disturbances including stomach pain, indigestion, and diarrhea.
Central nervous system effects such as dizziness, drowsiness, and blurred vision.
Musculoskeletal complaints including muscle pain, tenderness, or weakness which may be a precursor to rhabdomyolysis.
Risk of myopathy and rare cases of rhabdomyolysis leading to renal failure, especially when combined with statins.
Allergic reactions manifested by hives, facial or throat swelling, and breathing difficulties.
Hepatic effects including jaundice and elevated liver enzymes indicating hepatotoxicity.
Hematologic abnormalities such as low blood cell counts leading to anemia, easy bruising, or bleeding tendencies.
Numbness or tingling sensations, potentially related to peripheral neuropathy.
Sexual dysfunction including decreased libido and impotence.
Rare reports of cholelithiasis or gallbladder disease due to changes in bile composition.
Potential for hypoglycemia when combined with antidiabetic drugs, necessitating glucose monitoring.
Headache and fatigue reported in some patients during treatment.
Potential for vision changes including seeing halos around lights, requiring prompt evaluation.
Elevations in creatine kinase indicating muscle injury risk.
Drug-induced liver injury in susceptible individuals.

Precautions

Avoid use in patients with severe liver dysfunction due to altered metabolism and risk of toxicity.
Contraindicated in patients with severe renal impairment due to reduced elimination of gemfibrozil and metabolites.
Use cautiously in individuals with gallbladder disease or history of gallstones.
Monitor patients closely for signs of muscle pain or weakness, especially when used with statins or other myotoxic drugs.
Assess liver function tests prior to and during therapy to detect hepatotoxicity early.
Advise patients to avoid high-fat or cholesterol-rich diets to enhance the efficacy of gemfibrozil.
Instruct patients to report any unexplained muscle symptoms or dark urine promptly.
Careful medication reconciliation to prevent dangerous drug-drug interactions, particularly with warfarin and statins.
Use with caution during pregnancy and breastfeeding due to insufficient safety data; weigh benefits against potential risks.
Educate patients on the importance of adherence to dosing schedule, particularly taking gemfibrozil 30 minutes before meals.
Periodic complete blood count monitoring to detect potential hematologic adverse effects.
Avoid concurrent use with repaglinide, dasabuvir, or simvastatin due to contraindications and interaction risks.
Monitor blood glucose in diabetic patients as gemfibrozil may affect glycemic control.
Counsel patients regarding the avoidance of alcohol which may exacerbate hepatic side effects.
Consider dose adjustments or discontinuation in the event of severe adverse reactions.

Warnings

Do not use in patients with severe liver disease or impaired hepatic function.
Contraindicated in patients with severe renal impairment or dysfunction.
Avoid in patients with active gallbladder disease to prevent worsening cholelithiasis.
Contraindicated concomitant use with repaglinide, dasabuvir, or simvastatin due to risk of severe adverse effects.
Risk of rhabdomyolysis increased when used with certain cholesterol-lowering statins or other myopathy-inducing agents.
May cause serious allergic reactions including anaphylaxis; seek immediate medical attention if symptoms occur.
Use during pregnancy only if clearly necessary; risks to the fetus are not well established.
Breastfeeding is not recommended unless potential benefit justifies potential risk to the infant.
Potential for hepatotoxicity necessitates monitoring of liver enzymes.
Risk of serious bleeding if used concomitantly with anticoagulants such as warfarin; requires close monitoring.
Precaution advised in patients predisposed to hypoglycemia or those on antidiabetic medications.
Avoid abrupt discontinuation as it may adversely affect lipid management and cardiovascular risk.
Patients should be warned to seek medical attention for symptoms such as yellowing of skin or eyes, dark urine, or unexplained muscle pain.
Avoid in combination with medications that potently inhibit gemfibrozil metabolism unless benefits outweigh risks.
Potential for interaction with numerous drugs mandates thorough clinical evaluation before initiation.

Contraindication

Known hypersensitivity or allergy to gemfibrozil or any formulation components.
Severe hepatic impairment or active liver disease.
Severe renal dysfunction or failure.
Gallbladder disease including active cholelithiasis or biliary cirrhosis.
Concurrent use with repaglinide due to risk of severe hypoglycemia.
Concomitant use with dasabuvir due to significant interaction risks.
Concomitant use with simvastatin owing to increased risk of rhabdomyolysis.
Known history of statin-induced myopathy or rhabdomyolysis when considering combined therapy.
Pregnancy when risks outweigh benefits, given limited safety data.
Use in breastfeeding women unless necessary and benefits outweigh risks to infant.

Drug Interactions

Gemfibrozil significantly increases the risk of myopathy and rhabdomyolysis when used concomitantly with statin drugs such as atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and especially simvastatin.
Concomitant use with repaglinide is contraindicated due to increased risk of severe hypoglycemia resulting from inhibited metabolism of repaglinide.
Interaction with dasabuvir is contraindicated and may lead to increased plasma concentrations and toxicity of dasabuvir.
Gemfibrozil may potentiate the effects of warfarin and other oral anticoagulants, increasing bleeding risk and necessitating frequent INR monitoring.
Concurrent administration with colchicine can increase the risk of colchicine toxicity, including myopathy and neuromyopathy.
Drugs that share metabolic pathways, especially those metabolized by glucuronidation, may have altered plasma levels when combined with gemfibrozil.
Potential enhancement of hypoglycemic effects when used with antidiabetic agents, requiring close glucose monitoring.
May interact with certain antihypertensive agents, altering their efficacy through pharmacokinetic or pharmacodynamic effects.
Interactions with cyclosporine resulting in increased cyclosporine levels, potentially leading to nephrotoxicity and immunosuppression.
Concurrent use with bile acid sequestrants may reduce gemfibrozil absorption; staggered administration times are recommended.
Possible interaction with thyroid hormones, potentially altering dosing requirements.
Enhanced risk of hepatotoxicity when combined with other hepatotoxic drugs necessitates monitoring of liver function tests.
Potential interaction with oral contraceptives altering hormone metabolism.
Caution with concomitant use of antiretroviral drugs, as gemfibrozil may alter their plasma concentrations.
Interactions with over-the-counter supplements and herbal products cannot be excluded; clinical vigilance is advised.

Preparations Of The Drug

Gemfibrozil is formulated as immediate-release oral tablets.
Available strength: 600 mg per tablet.
Tablets designed for twice-daily administration, 30 minutes before meals.
Commercially marketed under the brand name Lopid.
Formulated for oral administration with standard excipients to enhance bioavailability and stability.
Packaging typically includes blister packs or bottles for dispensing.
Storage conditions require room temperature protection from moisture, heat, and light.
Prescribed as part of a multi-component lipid-lowering regimen including diet and exercise.
Prescribed as monotherapy or in combination with other lipid-lowering agents excluding contraindicated drugs.
Manufactured adhering to current Good Manufacturing Practices (cGMP) to ensure quality and purity.
Available as prescription-only medicine, requiring medical supervision during use.
Accompanied by patient information leaflets advising proper use and warning of potential side effects.
No liquid or injectable formulations are commercially available.
Tablets are scored for ease of swallowing but should not be split unless directed by a healthcare professional.
Preparation does not include extended-release or sustained-release formulations.